The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | The growing role of anti-PD1 inhibitors in the frontline treatment of HL
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses the growing role of anti-PD1 inhibitors in the treatment of Hodgkin lymphoma (HL) in the frontline setting, highlighting the efficacy and high overall response rate (ORR) observed with the use of these agents. Dr Bröckelmann also comments on the possibility of reducing the use of conventional chemotherapy, and the value of personalizing immunotherapeutic approaches and improving baseline risk stratification to improve patient outcomes. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: BeiGene, Bristol-Myers Squibb, MSD, Takeda
Research funding: BeiGene, Bristol-Myers Squibb, MSD, Takeda
Advisory boards: Takeda
Speakers’ bureau: BeiGene, MSD
